[Bacterial infections in cancer patients].
D000284:Administration, Oral; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy / Q000276:immunology / Q000451:nursing*; D002442:Ceftazidime / Q000627:therapeutic use*; D002939:Ciprofloxacin / Q000627:therapeutic use; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D009369:Neoplasms / Q000276:immunology*; D009894:Opportunistic Infections / Q000188:drug therapy / Q000276:immunology / Q000451:nursing*; D017410:Practice Guidelines as Topic; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000276:immunology
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D019980:Amoxicillin-Potassium Clavulanate Combination; D002442:Ceftazidime